- Recommendation ID
- NG100/6
- Question
Subcutaneous methotrexate:- What is the clinical and cost effectiveness of subcutaneous methotrexate compared with oral methotrexate for adults with early onset RA starting a new DMARD?
- Any explanatory notes
(if applicable) Why this is important:- Methotrexate is an important drug in the treatment of RA. Subcutaneous administration is an alternative option for people who have side effects with oral treatment. Evidence on the effectiveness of subcutaneous methotrexate is lacking, but its effects may be superior, due to increased bioavailability, and fewer side effects than with oral drugs. Research on subcutaneous methotrexate will inform future guideline recommendations.
Source guidance details
- Comes from guidance
- Rheumatoid arthritis in adults: management
- Number
- NG100
- Date issued
- July 2018
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 31/07/2018 |